PIASKY

This brand name is authorized in United States. It is also authorized in Austria, Estonia, France, Italy, Lithuania, Romania.

Active ingredients

The drug PIASKY contains one active pharmaceutical ingredient (API):

1	Crovalimab UNII H9KH1GP3UU - CROVALIMAB
	Crovalimab is a recombinant humanised immunoglobulin G1 (IgG1)-based monoclonal antibody that specifically binds with high affinity to component 5 (C5) of the complement system, inhibiting its cleavage into C5a and C5b and thus preventing the formation of the membrane attack complex (MAC). Crovalimab causes terminal complement activity inhibition. In patients with PNH, crovalimab inhibits terminal complement-mediated intravascular haemolysis.
	Read more about Crovalimab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PIASKY Solution for injection/infusion	MPI, EU: SmPC	European Medicines Agency (EU)
PIASKY Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AJ07		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AJ Complement inhibitors
Discover more medicines within L04AJ07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3089943
FR	Base de données publique des médicaments	67890915
IT	Agenzia del Farmaco	051476012
LT	Valstybinė vaistų kontrolės tarnyba	1100819
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W70528001
US	FDA, National Drug Code	50242-115